47results about "Nitro compound active ingredients" patented technology

A method for treating cancer or a tumor, in particular treating cancer by combining two drugs, relating to the field of cancer treatment. A method for treating cancer by combining a drug containing an AKR1C3 enzyme-activated compound and an immune checkpoint inhibitor / immune cell treatment drug. In particular, the immune checkpoint inhibitor is selected from an anti-PD -1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, etc., and the AKR1C3 enzyme-activated compound is selected from the compound of the following structure (I).

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

Provided here are compositions and methods for treatment of vascular conditions or respiratory conditions by administering a therapeutically effective amount of a nitrogen oxide compound and a nitrodilator. The nitrogen oxide compound can be nitrite, one or more of a number of nitro-group containing compounds, a nitrate-group containing compound, an NO donor, or an endogenous NO producing amino acid. The nitrodilator can be one or more of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, amyl nitrite, nitrosothiols, or dinitrosyl iron complexes.

The invention relates to a skin-compatible, nourishing, and protective agent for application to or treatment of the skin, comprising one or more active substances, in particular, but not exclusively, plant extracts or oils. According to the invention, a first mixture component is provided, which contains at least almond oil, cetyl alcohol, CBD isolate, and vitamin E or tocopherol, and a second mixture component is provided, which comprises sea salt dissolved in purified water, as well as xanthan gum and propylene glycol, wherein the first and second mixture components are combined and emulsified.

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The invention relates to an AKR1C3 enzyme expression level and medical application through KRAS mutation. According to the AKR1C3 enzyme activated anticancer prodrug, KRAS gene mutation can be directly used as a detection target before medication, namely, a KRAS mutation patient is a patient with high expression of the AKR1C3 enzyme and does not need to be subjected to AKR1C3 enzyme expression level or AKR1C3RNA detection, that is to say, KRAS mutation detection positive can be used as a screening index to screen the patient with high expression of the AKR1C3 enzyme.

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

The present invention provides the use of entacapone, an entacapone derivative, or a stereoisomer, hydrate, or pharmaceutically acceptable salt thereof, in a human in need thereof for treating an injury or promoting wound healing or tissue regeneration.

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and / or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and / or slowing down brain atrophy in a human subject in need thereof.

Provided herein are methods of treating vaginitis by simultaneous local application per vagina of both boric acid and nitroimidazole. Also provided are compositions useful in such treatments, for instance containing 100-1,000 mg of nitroimidazole and 300-900 mg boric acid. Vaginal application of nitroimidazole allows a higher but safe dose to be administered simultaneously with boric acid for the effective treatment of bacterial vaginosis (BV). Also provided are methods for prophylactic treatment of patients, such as those prone to recurrent BV.

Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1 / 027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and / or lusitropic dysfunction, and / or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

The present application relates to methods and compositions for treating epileptic disorders. The use of allosteric modulators and / or gaboxadol for treating an epileptic disorder in a subject in need thereof.

The present invention relates to the combination of meropenem and one or more antibiotic resistance breakers, pharmaceutical compositions containing the same, and methods for treating bacterial infections that include administering the same. Particularly, it relates to a pharmaceutical composition comprising (a) meropenem, (b) avibactam, and (c) EDTA.

Provided herein are compositions, systems, kits, and methods for applying a composition topically to a bodily area of a subject that has precancerous and / or cancerous cells (e.g., skin cancer cells) and / or is adjacent to underlying precancerous and / or cancerous cells, where the composition comprises N-phosphonacetyl-L-aspartate (PALA) (aka sparfosic acid) and water, and optionally further comprises at least one non-ionic surfactant.

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided. wherein the compounds comprise antibiotics suitable for use either alone or in combination with β-lactamase inhibitors and / or other antibiotics (including β-lactam and non-β-lactam antibiotics) in the treatment or prevention of bacterial infections.

The invention provides novel multifunctional conjugates of phenol-based mitochondrial uncoupler (e.g., 2, 4-dinitrophenol) and gemfibrozil, and derivatives thereof. The invention also provides pharmaceutical compositions comprising a compound of the invention and methods thereof for treating various diseases and disorders associated with or related to mitochondria or mitochondrial dysfunctions (e.g., neurodegenerative, metabolic and inflammatory diseases and disorders).

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitors and / or other antibiotics (including P-lactam and non-P-lactam antibiotics) in the treatment or prevention of bacterial infections.

The present invention relates generally to nitric oxide (NO) releasing nasal compositions and to methods of using the same.

The invention provides a preparation method of probiotics and application of the probiotics in prevention and treatment of helicobacter pylori. Furthermore, the probiotic composition for treating the helicobacter pylori is prepared from broad-spectrum antibacterial peptide, pediococcus pentosaceus CCTCC NO: M 2024601 and lactobacillus plantarum CCTCC M 2017459, and the composition prepared by combined use of the probiotics and the antibacterial peptide has a stronger broad-spectrum helicobacter pylori inhibition effect compared with the composition prepared by single use of the probiotics and the antibacterial peptide; animal experiments prove that the traditional Chinese medicine composition has the effect of eradicating helicobacter pylori and has a good application prospect.

Disclosed herein are novel NOS inhibitor compounds. Also disclosed herein, are methods for treating, ameliorating, and / or reducing the severity of NOS-related cancer, or a symptom associated therewith in a subject. The compounds described herein may be administered with a particular route of delivery, dosing regimen, and dosing schedule.

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and / or lusitropic dysfunction, and / or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

The present application provides the use of aromatic nitroethylenes, in particular, the present application provides the use of a compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof for preparing a medicament for modulating the dimer activity of nuclear receptor RXR or treating neurodegenerative diseases.

This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).

An injection preparation and a preparation method therefor, and a compatible medicinal liquid and a preparation method therefor. Upon performing tests, the provided injection preparation and compatible medicinal liquid thereof meet the requirements of long-term clinical trials and commercial production and sales. The injection preparation is a solution containing a compound of the following formula I, wherein the solvent of the solution contains C2-C8 alcohol, and can also contain another cosolvent or solubilizer. The preferred injection preparation is a mixed solution of DMA, ELP and ethanol which contains 10 mg / ml of a compound of formula (I), wherein DMA is a cosolvent, and ELP is a solubilizer. For the ready-to-use injection (compatible medicinal liquid) of the compound of following formula (I), the solvent thereof is water, the solute thereof comprises the compound of formula I, DMA, ELP, ethanol, an isosmotic adjusting agent and a pH regulator, the concentration of compound A in the injection is 0.016-1.10 mg / ml, the pH of the injection is 7.4, and the injection is an isosmotic solution. Further disclosed is a method for preparing the above-mentioned injection preparation and a method for preparing the above-mentioned compatible medicinal liquid of the injection.

A wound dressing 500 comprising a cover layer 501 configured to form a seal around a wound; a composite absorbent layer 502 comprising an activator gel and a nitrite source layer. The activator layer

The present invention relates to compositions and kits for generating nitric oxide. The compositions and kits include a nitrite salt, a reducing agent and an organic carboxylic acid. The compositions and kits of the present invention may be used in a variety of applications. In particular, the present invention relates to compositions, kits and methods using such compositions and kits for treating or preventing microbial infections.

The present invention provides a composition that has an effect of enhancing the gene expression of adrenomedullin.　One or more embodiments of the present invention pertain to a composition for enhancing adrenomedullin gene expression, said composition comprising a TRPV1 agonist and a TRPA1 agonist as active ingredients. Examples of the TRPV1 agonist include one or more selected from among capsaicin, 6-shogaol, 6-gingerol and piperine. Examples of the TRPA1 agonist include one or more selected from among allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and an oxylipin.